These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23280075)

  • 41. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans.
    Shin GT; Kim SJ; Ma KA; Kim HS; Kim D
    Am J Kidney Dis; 2000 Nov; 36(5):894-902. PubMed ID: 11054345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased urine transforming growth factor β1 (TGF-β1) and serum uric acid are associated with an early decline of glomerular filtration rate in kidney transplant recipients.
    Sibunruang C; Ingsathit A; Kantachuvesiri P; Radinahamed P; Rattanasiri S; Pootracool P; Kijvikai K; Sumethkul V; Kantachuvesiri S
    Transplant Proc; 2015 Mar; 47(2):304-8. PubMed ID: 25769564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ET(B) receptor cascade.
    El-Gowelli HM; Helmy MW; Ali RM; El-Mas MM
    Toxicol Appl Pharmacol; 2014 Mar; 275(2):88-95. PubMed ID: 24462674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Timing and value of protocol biopsies in well-matched kidney transplant recipients--a clinical and histopathologic analysis.
    Helanterä I; Ortiz F; Helin H; Räisänen-Sokolowski A; Honkanen E; Koskinen P
    Transpl Int; 2007 Nov; 20(11):982-90. PubMed ID: 17711407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of transforming growth factor-beta1 and hypoxia-inducible factor-1alpha in an experimental model of kidney transplantation.
    Lario S; Mendes D; Bescós M; Iñigo P; Campos B; Alvarez R; Alcaraz A; Rivera-Fillat F; Campistol JM
    Transplantation; 2003 May; 75(10):1647-54. PubMed ID: 12777850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TGF-beta1 in chronic allograft nephropathy following renal transplantation.
    Harris S; Coupes BM; Roberts SA; Roberts IS; Short CD; Brenchley PE
    J Nephrol; 2007; 20(2):177-85. PubMed ID: 17514622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
    Koziolek MJ; Riess R; Geiger H; Thévenod F; Hauser IA
    Kidney Int; 2001 Jul; 60(1):156-66. PubMed ID: 11422747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transforming growth factor-β activated long non-coding RNA ATB plays an important role in acute rejection of renal allografts and may impacts the postoperative pharmaceutical immunosuppression therapy.
    Qiu J; Chen Y; Huang G; Zhang Z; Chen L; Na N
    Nephrology (Carlton); 2017 Oct; 22(10):796-803. PubMed ID: 27414253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis.
    Del Prete D; Gambaro G; Lupo A; Anglani F; Brezzi B; Magistroni R; Graziotto R; Furci L; Modena F; Bernich P; Albertazzi A; D'Angelo A; Maschio G
    Kidney Int; 2003 Jul; 64(1):149-59. PubMed ID: 12787405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE; Salmela KT
    Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy: an insight for pathogenesis of its toxicity.
    Singh L; Singh G; Sharma A; Sinha A; Bagga A; Dinda AK
    Hum Pathol; 2015 Jan; 46(1):34-9. PubMed ID: 25449629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gingival crevicular fluid transforming growth factor-beta1 in cyclosporine and tacrolimus treated renal transplant patients without gingival overgrowth.
    Gürkan A; Afacan B; Emingil G; Töz H; Başkesen A; Atilla G
    Arch Oral Biol; 2008 Aug; 53(8):723-8. PubMed ID: 18342291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants.
    Bicknell GR; Williams ST; Shaw JA; Pringle JH; Furness PN; Nicholson ML
    Br J Surg; 2000 Nov; 87(11):1569-75. PubMed ID: 11091247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi.
    Becker LE; Weritz B; Yi X; Gross-Weissmann ML; Waldherr R; Zeier M; Sommerer C
    Transpl Int; 2015 May; 28(5):553-64. PubMed ID: 25630217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data.
    Pape L; Lehner F; Blume C; Ahlenstiel T
    Transplantation; 2011 Sep; 92(6):658-62. PubMed ID: 21804444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.
    Hazzan M; Buob D; Labalette M; Provot F; Glowacki F; Hoffmann M; Copin MC; Noel C
    Transplantation; 2006 Sep; 82(5):657-62. PubMed ID: 16969289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.